{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:16:02Z","timestamp":1790266562032,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jaci.2017.11.015","type":"journal-article","created":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T13:32:48Z","timestamp":1512999168000},"page":"928-941.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1851-1429","authenticated-orcid":false,"given":"Valentina","family":"Capo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carmina","family":"Castiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marita","family":"Bosticardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Draghici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi P.","family":"Poliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Sergi Sergi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosita","family":"Rigoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Cassani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Zanussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Carrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9524-8492","authenticated-orcid":false,"given":"Paolo","family":"Uva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry","family":"Dobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Sacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi D.","family":"Notarangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niek P.","family":"van Til","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Wagemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2017.11.015_bib1","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nri.2016.28","article-title":"Human RAG mutations: biochemistry and clinical implications","volume":"16","author":"Notarangelo","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2017.11.015_bib2","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaci.2014.04.042","article-title":"A hypomorphic recombination-activating gene 1 (RAG1) mutation resulting in a phenotype resembling common variable immunodeficiency","volume":"134","author":"Abolhassani","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.11.015_bib3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s10875-015-0146-4","article-title":"RAG1 deficiency may present clinically as selective IgA deficiency","volume":"35","author":"Kato","year":"2015","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2017.11.015_bib4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10875-014-0121-5","article-title":"Identification of patients with RAG mutations previously diagnosed with common variable immunodeficiency disorders","volume":"35","author":"Buchbinder","year":"2015","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2017.11.015_bib5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/pai.12684","article-title":"Late-onset combined immune-deficiency due to LIGIV mutations in a 12 years old patient","volume":"28","author":"Cifaldi","year":"2017","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.jaci.2017.11.015_bib6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJM196508192730806","article-title":"Familial reticuloendotheliosis with eosinophilia","volume":"273","author":"Omenn","year":"1965","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.11.015_bib7","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0092-8674(00)81448-8","article-title":"Partial V(D)J recombination activity leads to omenn syndrome","volume":"93","author":"Villa","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2017.11.015_bib8","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1182\/blood.V97.9.2772","article-title":"Identical mutations in RAG1 or RAG2 genes leading to defective V(D)J recombinase activity can cause either T-B-severe combined immune deficiency or Omenn syndrome","volume":"97","author":"Corneo","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2017.11.015_bib9","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1084\/jem.20091927","article-title":"Expansion of immunoglobulin-secreting cells and defects in B cell tolerance in Rag-dependent immunodeficiency","volume":"207","author":"Walter","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2017.11.015_bib10","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1172\/JCI80477","article-title":"Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency","volume":"125","author":"Walter","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2017.11.015_bib11","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1084\/jem.20091928","article-title":"Homeostatic expansion of autoreactive immunoglobulin-secreting cells in the Rag2 mouse model of Omenn syndrome","volume":"207","author":"Cassani","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2017.11.015_bib12","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1056\/NEJMoa1401177","article-title":"Transplantation outcomes for severe combined immunodeficiency, 2000-2009","volume":"371","author":"Pai","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.11.015_bib13","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood.V99.3.872","article-title":"Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival","volume":"99","author":"Myers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2017.11.015_bib14","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jpeds.2009.07.049","article-title":"Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis","volume":"155","author":"Railey","year":"2009","journal-title":"J Pediatr"},{"key":"10.1016\/j.jaci.2017.11.015_bib15","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.jaci.2010.06.015","article-title":"Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better?","volume":"126","author":"Gennery","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.11.015_bib16","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10875-012-9797-6","article-title":"Post-transplantation B cell function in different molecular types of SCID","volume":"33","author":"Buckley","year":"2013","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaci.2017.11.015_bib17","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.bbmt.2016.12.619","article-title":"Current knowledge and priorities for future research in late effects after hematopoietic stem cell transplantation (HCT) for severe combined immunodeficiency patients: a consensus statement from the Second Pediatric Blood and Marrow Transplant Consortium","volume":"23","author":"Heimall","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaci.2017.11.015_bib18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1182\/blood-2013-01-476432","article-title":"SCID patients with ARTEMIS vs RAG deficiencies following HCT: Increased risk of late toxicity in ARTEMIS-deficient SCID","volume":"123","author":"Schuetz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2017.11.015_bib19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1089\/hum.2015.137","article-title":"Gene therapy for X-linked severe combined immunodeficiency: where do we stand?","volume":"27","author":"Cavazzana","year":"2016","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jaci.2017.11.015_bib20","doi-asserted-by":"crossref","first-page":"335ra57","DOI":"10.1126\/scitranslmed.aad8856","article-title":"Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency","volume":"8","author":"De Ravin","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2017.11.015_bib21","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa0805817","article-title":"Gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"360","author":"Aiuti","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2017.11.015_bib22","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1182\/blood-2012-02-400937","article-title":"Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans","volume":"120","author":"Candotti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2017.11.015_bib23","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jaci.2013.10.009","article-title":"Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome","volume":"133","author":"Van Til","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.11.015_bib24","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/leu.2011.106","article-title":"Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer","volume":"25","author":"Pike-Overzet","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2017.11.015_bib25","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1182\/blood-2002-03-0782","article-title":"Gene therapy of RAG-2-\/- mice: sustained correction of the immunodeficiency","volume":"100","author":"Yates","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2017.11.015_bib26","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1038\/mt.2012.110","article-title":"Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene","volume":"20","author":"van Til","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaci.2017.11.015_bib27","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1172\/JCI30928","article-title":"A hypomorphic R229Q Rag2 mouse mutant recapitulates human Omenn syndrome","volume":"117","author":"Marrella","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2017.11.015_bib28","doi-asserted-by":"crossref","first-page":"9088","DOI":"10.1128\/JVI.00485-12","article-title":"Safer, silencing-resistant lentiviral vectors: optimization of the ubiquitous chromatin-opening element through elimination of aberrant splicing","volume":"86","author":"Knight","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.jaci.2017.11.015_bib29","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2012-01-406827","article-title":"Anti-CD3e mAb improves thymic architecture and prevents autoimmune manifestations in a mouse model of Omenn syndrome: therapeutic implications","volume":"120","author":"Marrella","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2017.11.015_bib30","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/mt.2014.87","article-title":"Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis","volume":"22","author":"Chiriaco","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaci.2017.11.015_bib31","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2009.31","article-title":"Evidence for long-term efficacy and safety of gene therapy for Wiskott-Aldrich syndrome in preclinical models","volume":"17","author":"Marangoni","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaci.2017.11.015_bib32","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jaci.2011.03.030","article-title":"Lentiviral-mediated gene therapy leads to improvement of B-cell functionality in a murine model of Wiskott-Aldrich syndrome","volume":"127","author":"Bosticardo","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.11.015_bib33","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1365-2249.2006.03251.x","article-title":"Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes","volume":"147","author":"Li","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jaci.2017.11.015_bib34","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1084\/jem.194.8.1151","article-title":"Homeostasis of peripheral B cells in the absence of B cell influx from the bone marrow","volume":"194","author":"Hao","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2017.11.015_bib35","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1084\/jem.20151116","article-title":"Intestinal microbiota sustains inflammation and autoimmunity induced by hypomorphic RAG defects","volume":"213","author":"Rigoni","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2017.11.015_bib36","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1172\/JCI200523087","article-title":"AIRE deficiency in thymus of 2 patients with Omenn syndrome","volume":"115","author":"Cavadini","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2017.11.015_bib37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/imr.12419","article-title":"Autoimmune regulator and self-tolerance\u2014molecular and clinical aspects","volume":"271","author":"Abramson","year":"2016","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaci.2017.11.015_bib38","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.cell.2015.10.013","article-title":"Fezf2 orchestrates a thymic program of self-antigen expression for immune tolerance","volume":"163","author":"Takaba","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jaci.2017.11.015_bib39","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/nri2621","article-title":"Signalling crosstalk in B cells: managing worth and need","volume":"9","author":"Cancro","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2017.11.015_bib40","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1182\/blood-2008-09-177923","article-title":"Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency","volume":"113","author":"Neven","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2017.11.015_bib41","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.molmed.2016.02.002","article-title":"Treating immunodeficiency through HSC gene therapy","volume":"22","author":"Booth","year":"2016","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jaci.2017.11.015_bib42","first-page":"259","article-title":"Rag defects and thymic stroma: lessons from animal models","volume":"5","author":"Marrella","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2017.11.015_bib43","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1189\/jlb.0713365","article-title":"Hypomorphic mutation in the RAG2 gene affects dendritic cell distribution and migration","volume":"94","author":"Maina","year":"2013","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.jaci.2017.11.015_bib44","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/blood-2009-03-211029","article-title":"Early defects in human T-cell development severely affect distribution and maturation of thymic stromal cells: possible implications for the pathophysiology of Omenn syndrome","volume":"114","author":"Poliani","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2017.11.015_bib45","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1084\/jem.20051038","article-title":"Characterization of marginal zone B cell precursors","volume":"202","author":"Srivastava","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2017.11.015_bib46","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nm.4313","article-title":"Refining strategies to translate genome editing to the clinic","volume":"23","author":"Cornu","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2017.11.015_bib47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev-genet-110410-132552","article-title":"V(D)J recombination: mechanisms of initiation","volume":"45","author":"Schatz","year":"2011","journal-title":"Annu Rev Genet"},{"key":"10.1016\/j.jaci.2017.11.015_bib48","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2010.02.012","article-title":"B-cell function in severe combined immunodeficiency after stem cell or gene therapy: a review","volume":"125","author":"Buckley","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.11.015_bib49","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.jaci.2013.01.047","article-title":"B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment?","volume":"131","author":"Haddad","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.11.015_bib50","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ymthe.2017.03.018","article-title":"Evolving gene therapy in primary immunodeficiency","volume":"25","author":"Thrasher","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaci.2017.11.015_bib51","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jaci.2016.12.978","article-title":"Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies","volume":"140","author":"Fischer","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.11.015_bib52","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood-2014-06-583260","article-title":"Autoimmune and other cytopenias in primary immunodeficiencies: pathomechanisms, novel differential diagnoses, and treatment","volume":"124","author":"Seidel","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2017.11.015_bib53","doi-asserted-by":"crossref","first-page":"310","DOI":"10.12688\/f1000research.7512.1","article-title":"Advances of gene therapy for primary immunodeficiencies","volume":"5","author":"Candotti","year":"2016","journal-title":"F1000Research"},{"key":"10.1016\/j.jaci.2017.11.015_bib54","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature13420","article-title":"Targeted genome editing in human repopulating haematopoietic stem cells","volume":"510","author":"Genovese","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2017.11.015_bib55","doi-asserted-by":"crossref","first-page":"eaah3480","DOI":"10.1126\/scitranslmed.aah3480","article-title":"CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease","volume":"9","author":"De Ravin","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2017.11.015_bib56","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jaci.2017.01.007","article-title":"New frontiers in the therapy of primary immunodeficiency: from gene addition to gene editing","volume":"139","author":"Kohn","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2017.11.015_bib57","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/MOH.0000000000000385","article-title":"The changing landscape of gene editing in hematopoietic stem cells: a step towards Cas9 clinical translation","volume":"24","author":"Dever","year":"2017","journal-title":"Curr Opin Hematol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917318869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674917318869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:12:10Z","timestamp":1758791530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674917318869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0091674917318869"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2017.11.015","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732304849.793555462","asserted-by":"object"}]},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of lentivirus-mediated gene therapy in an Omenn syndrome recombination-activating gene 2 mouse model is not hindered by inflammation and immune dysregulation","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2017.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}